Retatrutide vs Tirzepatide.
Tirzepatide is FDA-approved and battle-tested. Retatrutide adds a third receptor (glucagon) and is producing the largest weight-loss numbers ever recorded in trials. Here's how they actually stack up.
Same family, same fundamentals.
Both are weekly subcutaneous injections, both hit GLP-1 and GIP receptors, both produce significant fat loss alongside appetite suppression. The dosing math, the titration cadence, and the GI side effect curve all look broadly similar.
Both are stacked on the same backbone — you can think of retatrutide as tirzepatide plus a third receptor. That third receptor (glucagon) is where the comparison gets interesting.
The differences that actually matter.
Glucagon receptor activation is what separates retatrutide from tirzepatide. Glucagon raises hepatic glucose output and, more importantly for weight loss, increases resting energy expenditure. Tirzepatide suppresses appetite. Retatrutide suppresses appetite AND turns up the metabolic burn rate. The result in trials: 24% body-weight loss at 48 weeks with the curve still descending — meaning real-world maximum loss is likely higher than the trial number.
Tirzepatide has a 4-year track record in pharmacies and pharmacovigilance data on hundreds of thousands of patients. Retatrutide is still in Phase 3 — the safety profile looks clean so far, but the long tail of rare adverse events isn't characterized yet. If you're risk-averse, that gap matters.
Nausea on retatrutide is meaningfully worse at equivalent escalation steps. Most users find they need to titrate slower than the tirzepatide schedule — 6 weeks per step instead of 4 — to keep GI side effects tolerable. The glucagon arm also can elevate fasting glucose temporarily in early weeks; this normalizes but is worth watching if you're prediabetic.
Which one fits your goal.
If you've maxed tirzepatide at 15 mg/week and you're still losing weight (i.e. it's still working), stay on tirzepatide. There's no reason to switch tools when the current one is delivering.
If you've maxed tirzepatide and plateaued — the curve has truly flattened for 2–3 months — retatrutide is the rational next step. The triple-agonist mechanism gives you a new axis of action that tirzepatide can't reach.
If you're new to GLP-1s entirely, start with semaglutide or tirzepatide. Retatrutide is a graduate-level tool, not a starter — you want to know how your body responds to the simpler mechanism first.
Reconstitute either one in seconds.
Common questions.
Is retatrutide stronger than tirzepatide?+
By weight-loss percentage in 48-week trials, yes — 24% vs 22% at peak doses. But the more interesting fact is that the retatrutide curve hadn't plateaued at 48 weeks, while tirzepatide's had. The long-run ceiling is meaningfully higher.
Can I run them together?+
No useful reason to. They overlap on GLP-1 and GIP completely, so stacking them is mostly just doubling the dose of the shared receptors. If you want more weight loss, escalate one — don't stack.
Why isn't retatrutide FDA-approved yet?+
Phase 3 trials are still running as of 2026. Approval is expected in 2026–2027 for obesity. The research-peptide market is well ahead of the FDA timeline here, which is why you can already buy it for personal use even though it's not in pharmacies.